Peer Reviewed Publications in Print or Other Media
Sewastianik, T., Jiang, M., Sukhdeo, K., Patel, S. S., Roberts, K., Kang, Y., Alduaij, A., Dennis, P. S., Lawney, B., Liu, R., Song, Z., Xiong, J., Zhang, Y., Lemieux, M. E., Pinkus, G. S., Rich, J. N., Weinstock, D. M., Mullighan, C. G., Sharpless, N. E., & Carrasco, R. D. (2017). Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice. Blood Advances, 1(25), 2361-2374
Inhibition of USP10 induces degradation of oncogenic FLT3
Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec;13(12):1207-1215.
PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Res. 2017 Nov 1;77(21):e62-e66.
A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas
Ryan RJH, Petrovic J, Rausch DM, Zhou Y, Lareau CA, Kluk MJ, Christie AL, Lee WY, Tarjan DR, Guo B, Donohue LKH, Gillespie SM, Nardi V, Hochberg EP, Blacklow SC, Weinstock DM, Faryabi RB, Bernstein BE, Aster JC, Pear WS. A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. Cell Rep. 2017 Oct 17;21(3):784-797.
Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, Griffin JD. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Jul 6;8(32):52026-52044.
Weigert O, Weinstock DM. The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. Blood. 2017 Sep 28;130(13):1491-1498
Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA
Day TA, Layer JV, Cleary JP, Guha S, Stevenson KE, Tivey T, Kim S, Schinzel AC, Izzo F, Doench J, Root DE, Hahn WC, Price BD, Weinstock DM. Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun. 2017 Jun 13;8:15918.
The Promise of organ and tissue preservation to transform medicine
Sebastian Giwa, Jedediah K Lewis, Luis Alvarez, Robert Langer, Alvin E Roth, George M Church, James F Markmann, David H Sachs, Anil Chandraker, Jason A Wertheim, Martine Rothblatt, Edward S Boyden, Elling Eidbo, W P Andrew Lee, Bohdan Pomahac, Gerald Brandacher, David M Weinstock, Gloria Elliott, David Nelson, Jason P Acker, Korkut Uygun, Boris Schmalz, Brad P Weegman, Alessandro Tocchio, Greg M Fahy, Kenneth B Storey, Boris Rubinsky, John Bischof, Janet A W Elliott, Teresa K Woodruff, G, John Morris, Utkan Demirci, Kelvin G M Brockbank, Erik J Woods, Robert N Ben, John G Baust, Dayong Gao, Barry Fuller, Yoed Rabin, David C Kravitz, Michael J Taylor, Mehmet Toner. The Promise of organ and tisse preservation to transform medicine. Nat Biotechnol. 2017 Jun 7; 35(6): 530–542.doi:10.1038/nbt.3889
Functional Proteogenomics Reveals Biomarkers and Therapeutic Targets in Lymphomas
Rolland DCM, Basrur V, Jeon YK, McNeil-Schwalm C, Fermin D, Conlon KP, Zhou Y, Ng SY*, Tsou CC, Brown NA, Thomas DG, Bailey NG, Omenn GS, Nesvizhskii AI, Root DE, Weinstock DM, Faryabi RB, Lim MS, Elenitoba-Johnson KSJ. Functional Proteogenomics Reveals Biomarkers and Therapeutic Targets in Lymphomas. Proceedings of the National Academy of Sciences 2017;114:6581-6.
PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA.
Day TA*, Layer JV*, Cleary JP*, Guha S*, Stevenson KE, Tivey T*, Kim S*, Schinzel AC, Izzo F, Doench J, Root DE, Hahn WC, Price BD, Weinstock DM. PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nature Communications 2017;8:15110
Ajore R, Raiser D, McConkey M, Joud M, Boidol B, Mar B, Saksena G, Weinstock DM, Armstrong S, Ellis SR, Ebert BL, Nilsson B. Deletion of ribosomal protein genes is a common vulnerability in human cancer, particularly in concert with TP53 mutation. EMBO Mol Med 2017;9:498-507
Akahane K, Li Z, Etchin J, Berezovskaya A, Gjini E, Masse CE, Miao W, Rocnik J, Kapeller R, Greenwoods JR, Tiv H, Sanda T, Weinstock DM, Look AT. Anti-leukemic Activity of the TYK2 selective inhibitor NDI-031301 in T-cell Acute Lymphoblastic Leukemia. Brit J Haematology 2017;177:271-82
Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia
Pikman Y, Alexe G, Roti G, Conway AS, Furman A, Lee AS, Place AE, Kim S, Saran C, Modiste R, Weinstock DM, Harris M, Kung AL, Silverman LB, Stegmaier K. Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia. Clin Cancer Res 2017;23(4):1012-24
Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen r, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA*, LaCasce A, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddizi T, Sohani AR, Zain J, Rosen ST, Kwak L W, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Onc 2017;35(1):24-31
Escape from X-Inactivation Tumor Suppressor (EXITS) genes contribute to cancer sex bias
Dunford A^, Weinstock DM^, Savova V, Schumacher SE, Cleary JP*, Yoda A*, Sullivan TJ, Gimelbrant AA, Beroukhim R, Lawrence MS^, Getz G^, Lane AA^*. Escape from X-Inactivation Tumor Suppressor (EXITS) genes contribute to cancer sex bias. ^equal contribution Nature Genetics 2017;49:10-16
Other Peer-Reviewed Publications
Meehan TF, Conte N, Goldstein TC, Inghirami G, Murakami MA*, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush M, Byrne AT, Caldas C, Christie AL, Clark D, Dowst H, Dry JR, Doroshow J, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt DM, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KK, Mason JC, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Research [in press].
Giwa S, Lewis J, Langer R, Church GM, Sachs D, Markmann J, Boyden E, Lee A, Alvarez L, Elliott G, Weinstock DM, Acker J, Pomahac B, Uygun MK, Eidbo E, Schmalz B, Tocchio A, Weegman B, Fahy G, Rubinsky B, Bischof J, Elliott J, Brandacher G, Storey K, Nelson D, Woodruff T, Demirci U, Brockbank K, Woods E, Ben R, Baust JG, Gao D, Fuller B, Rabin Y, Kravitz D, Taylor MJ, Toner M. The Promise of Organ and Tissue Preservation to Transform Medicine. Nature Biotechnology 2017;35:530-42
Reviews, Chapters, Monographs and Editorials
Murakami M, Weinstock DM. The next best thing. Nature 2017
Yoshida N, Weinstock DM. It takes a village to unmask HSTL. Cancer Disc 2017;7:352-3